TheraRadar
← Back
Data updated: Jul 17, 2026

SUNSHINE LAKE

Pharma
Infectious DiseaseOncologyRespiratory Execution: Good

SUNSHINE LAKE is a pharmaceutical company focused on Infectious Disease, Oncology, Respiratory.

-
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

SUNSHINE LAKE at a Glance

  • Fast trial execution (12 months median completion)

SUNSHINE LAKE's Key Drugs

SUNSHINE LAKE's core commercial portfolio centers on TENOFOVIR ALAFENAMIDE, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.

TENOFOVIR ALAFENAMIDE
Infectious Disease
Approved 2023

SUNSHINE LAKE's Recent FDA Approvals

New NDA/BLA approvals for SUNSHINE LAKE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SUNSHINE LAKE's Therapeutic Areas

SUNSHINE LAKE's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 39%
0 drugs Phase 3: 1 Phase 2: 5 Phase 1: 15
Oncology 27%
0 drugs Phase 3: 2 Phase 1: 12
Respiratory 19%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 6
Metabolic 14%
0 drugs Phase 3: 1 Phase 1: 6
Neurology 1%
0 drugs Phase 1: 1

SUNSHINE LAKE's Top Competitors

SUNSHINE LAKE's closest competitors by therapeutic-area and drug-target overlap include Merck, GSK, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Oncology, Infectious Disease, Metabolic, Respiratory
GSK big-pharma
Respiratory, Infectious Disease, Oncology, Metabolic
Pfizer big-pharma
Oncology, Infectious Disease, Neurology
GE HEALTHCARE specialty
Neurology, Infectious Disease, Oncology, Respiratory
AbbVie big-pharma
Oncology, Infectious Disease, Neurology

SUNSHINE LAKE Pipeline Snapshot

SUNSHINE LAKE has 52 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 7 Phase 2 and 40 Phase 1.

5
Phase 3
7
Phase 2
40
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q3 2026
Lerotinib
Esophageal Cancer
Estimated · stale NCT04415853

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • TENOFOVIR ALAFENAMIDE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/5 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges